MTOR and neoplasm: Somatic mutations in multiple endocrine neoplasia type 1 and death domain associated protein/α-thalassemia, mental retardation, X-linked have been identified in 44% and 43% of pNETs, respectively, while 14% of tumor samples exhibited mutations in mTOR and related pathways, including phosphatase and tensin homolog, tuberous sclerosis complex 2, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [32].